日前，Saol Therapeutics宣布，美国FDA已受理其在研疗法SL1009的新药申请（NDA），用于治疗丙酮酸脱氢酶复合物缺乏症（PDCD）。FDA已授予该申请优先审评资格，并设定PDUFA日期为2025年5月27日。

Researchers have developed a new method for growing T cells in the lab, allowing them to survive longer and fight cancer more effectively. This advancement, detailed in Cell Metabolism, could ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug ...

Nylon, the durable and elastic material, is like other plastics made from chemicals found in fossil fuels. Biodegradable plastics based on biomass-derived compounds are attracting attention as an ...

Nylon, the durable and elastic material, is like other plastics made from chemicals found in fossil fuels. Biodegradable plastics based on ...

Osaka Metropolitan University scientists have developed an artificial photosynthesis technology that produces precursors of biodegradable nylon from biomass-derived compounds and ammonia.

Bioengineering and Environmental Sciences Lab, Department of Energy and Environmental Engineering, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad 500007, India ...

According to Cour, CNP-104 initiates tolerance to pathogenic activated pyruvate dehydrogenase complex-E2 T-cells that “drive inflammation in bile ducts, leading to improvement in clinical outcom ...